home / stock / allk / allk news

ALLK News and Press, Allakos Inc. From 08/06/19

Stock Information
Company Name: Allakos Inc.
Stock Symbol: ALLK
Market: NASDAQ
Website: allakos.com
Menu
ALLK ALLK Quote ALLK Short ALLK News ALLK Articles ALLK Message Board
Get ALLK Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLK - ALLK, ADNT, GSKY and PODD among midday movers

Gainers:  EverQuote (NASDAQ: EVER ) +47% . NeoPhotonics Corporation (NYSE: NPTN ) +27% . Invacare Corporation (NYSE: IVC ) +23% . Adient plc (NYSE: ADNT ) +23% . Ducommun Incorporated (NYSE: DCO ) +22% . Insulet Corporation (NASDAQ: PODD ) +19% . Greenlight Capital Re (NASDAQ: G...
ALLK - Allakos Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and oth...

ALLK - ALLK, DO, GFI and SA among midday movers

Gainers: Allakos (NASDAQ: ALLK ) +129% . MediWound (NASDAQ: MDWD ) +15% . Four Seasons Education (Cayman) (NYSE: FEDU ) +12%  KemPharm (NASDAQ: KMPH ) +12% .  Sandstorm Gold (NYSEMKT: SAND ) +11% . Endeavour Silver (NYSE: EXK ) +10% . MoneyGram International (NASDAQ: MGI )...

ALLK - RIOT, MARA among premarket gainers

Allakos (NASDAQ: ALLK )  +97%  on positive AK002 data and Q2 results . More news on: Allakos Inc., Riot Blockchain, Inc., Marathon Patent Group, Inc., Stocks on the move Read more ...

ALLK - Allakos up 77% premarket on positive AK002 data

Thinly traded Allakos (NASDAQ: ALLK ) is up  77%  premarket on increased volume following its announcement of positive data from a Phase 2 clinical trial, ENIGMA , evaluating lead candidate AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. More...

ALLK - Allakos EPS beats by $0.03

Allakos (NASDAQ: ALLK ): Q2 GAAP EPS of -$0.44  beats by $0.03 . More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ALLK - Allakos Reports Second Quarter 2019 Financial Results

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the second quarter ended June...
ALLK - Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001) Treatment response secondary endpoint met with 69% of AK002 treated patients meeting the response criteria vs. 5% on placebo (p = 0.0008) Total symptom...

ALLK - Allakos reports Q1 results

Allakos (NASDAQ: ALLK ): Q1 GAAP EPS of -$0.47. More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ALLK - Allakos Reports First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 20...
Previous 10 Next 10